1. Home
  2. CATX vs AGEN Comparison

CATX vs AGEN Comparison

Compare CATX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perspective Therapeutics Inc.

CATX

Perspective Therapeutics Inc.

HOLD

Current Price

$2.99

Market Cap

341.0M

Sector

Health Care

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$6.84

Market Cap

274.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CATX
AGEN
Founded
1983
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
341.0M
274.8M
IPO Year
2018
1999

Fundamental Metrics

Financial Performance
Metric
CATX
AGEN
Price
$2.99
$6.84
Analyst Decision
Strong Buy
Buy
Analyst Count
9
2
Target Price
$12.11
$14.50
AVG Volume (30 Days)
1.3M
8.6M
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
0.96
Revenue
N/A
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$6.82
Revenue Growth
N/A
89.95
52 Week Low
$1.96
$2.71
52 Week High
$6.16
$8.85

Technical Indicators

Market Signals
Indicator
CATX
AGEN
Relative Strength Index (RSI) 47.01 60.81
Support Level $2.82 $3.09
Resistance Level $4.27 $8.70
Average True Range (ATR) 0.15 0.73
MACD 0.02 -0.03
Stochastic Oscillator 62.77 47.35

Price Performance

Historical Comparison
CATX
AGEN

About CATX Perspective Therapeutics Inc.

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: